Single‐Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment

Azilsartan medoxomil (AZL‐M) is a potent angiotensin II receptor blocker that decreases blood pressure in a dose‐dependent manner. It is a prodrug that is not detected in blood after its oral administration because of its rapid hydrolysis to the active moiety, azilsartan (AZL). AZL undergoes further...

Descripción completa

Detalles Bibliográficos
Autores principales: Dudkowski, Caroline, Karim, Aziz, Zhao, Zhen, Alonso, Alberto B., Garg, Dyal, Preston, Richard A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Special Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763333/
https://www.ncbi.nlm.nih.gov/pubmed/28750149
http://dx.doi.org/10.1002/jcph.970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763333/
https://www.ncbi.nlm.nih.gov/pubmed/28750149
http://dx.doi.org/10.1002/jcph.970

Ejemplares similares